Glioma misto em um cão: relato de caso

Intracranial neoplasms are common causes of neurological disorders in middle-aged and elderly dogs. With the feasibility of computed tomography, it is now possible to determine the extent and exact location of brain tumors, identifying them ante mortem in dogs and cats. This paper aims to report the occurrence of a mixed glioma in a Boxer dog examined at the Veterinary Hospital of Unesp, Botucatu Campus. The animal presented with a brain syndrome of acute onset and progressive course. CT scan showed the presence of a mass in the right cerebral hemisphere extending from the frontal to the parietal region and involving the basal ganglia. Given the gravity of the neurological disorder, the owner chose to perform euthanasia. Microscopic analysis of the mass allowed the diagnosis of mixed glioma.

Inibidores de tirosina-quinase no tratamento de mastocitomas cutâneos em cães: revisão

The mast cell tumor (MCT) is the second most common type of tumor in dogs. It is characterized by uncontrolled proliferation of mast cells in the skin. Treatment involves surgical resection, chemotherapy and radiotherapy. Recently, new treatment protocols have been developed, such as the use of tyrosine kinase inhibitors. With the increasing knowledge about the genome and the evolution of methods in molecular genetics, drugs with specific molecular targets are surely going to become promising therapeutic modalities in the near future. Besides being involved in the normal cell cycle, some studies suggest that tyrosine kinases have a fundamental role in neoplastic processes. Therefore, some strategies such as the development of antibodies anti-receptors for tyrosine kinases and small-molecule tyrosine kinase receptor inhibitors have been developed in an attempt to inhibit tumor development. The purpose of this review is to describe the use of tyrosine kinase inhibitors in the treatment of mast cell tumors in dogs.

Hiperadrenocorticismo em cães: revisão

Hyperadrenocorticism is a relatively common endocrinopathy in dogs, which is associated to an excessive production or administration of cortisol. The most affected breeds are Poodles, Teckels, Boxers, Boston Terriers and Beagles. The clinical signs most commonly observed are polyuria, polydipsia, polyfagia, panting, distended abdomen, endocrine alopecia, muscular weakness and lethargy. Laboratorial abnormalities include stress leukogram, increase in alkaline phosphatase and alanine aminotransferase activities, hypercholesterolemia, lipemia, hyperglycemia and hyposthenuria. The preferred essay to evaluate adrenal gland function is the low-dose dexamethasone suppression test, whereas the most used treatments include mitotane and trilostane. The objective of this paper is to review hyperadrenocorticism in dogs, because this disease is relatively common in small animal clinics and has many long-term complications.

Características tomográficas de neoplasias encefálicas primárias em cães

Computed tomography (CT) can be considered an important test to identify the presence of primary brain neoplasias in dogs. CT results can help define the type of brain tumor when associated with clinical findings. It allows the identification of lesions and their features, such as size, location, compression and invasion of adjacent tissue. One must analyze the density, mass effect, peritumoral edema, calcification, and image enhancement after intravenous injection of contrast medium. Gliomas, meningiomas and tumors of the choroid plexus and pituitary are the most common primary brain neoplasms diagnosed by CT in dogs. The aim of this paper is to review the literature related to primary brain tumors and report their most important tomographic features, in order to help clinicians achieve a presumptive diagnosis of tumor type.

Espresión de la ciclooxigenasa-2 en los carcinomas mamarios caninos primarios metastáticos y no metastáticos

The aim of this study was to detect the expression of ciclooxigenase-2 (COX-2) in metastatic primary carcinoma and non metastatic carcinoma, taking into consideration the relation between COX-2 and the progression of cancer. Evaluation of the COX-2 expression was achieved by immunohistochemistry analysis, using the primary polyclonal antibody anti-PGHS-2, clone PG 27, (Oxford Biomedical Research). The number of marked cells by the COX-2 antibody was higher (P < 0.001) in the metastatic primary carcinoma (81.25%) than non-metastatic (60.3%). There was a positive correlation between the number of labeled cells.